cGMP Consulting logo -Celebrating 25 Years

About Celine Lam

This author has not yet filled in any details.
So far Celine Lam has created 102 blog entries.

Escaping Pilot Purgatory: Scaling Digital Manufacturing From Proof of Concept to the Plant Floor

Scaling Pharma 4.0 digital manufacturing cannot be treated as a matter of extending a successful pilot across the plant. For pharmaceutical manufacturers, moving digital initiatives from proof of concept to production requires designing for validation, data governance, integration, and adoption from the outset, and governing the portfolio with the discipline to stop weak pilots early and advance strong ones quickly.

2026-10-23T16:14:31+00:00October 29th, 2026|White Papers|

The Unowned Risk: Cybersecurity as a Quality Obligation in GxP Environments

Cybersecurity has become an essential component of regulatory compliance for pharmaceutical and medical device manufacturers. This white paper examines the growing connection between GxP cybersecurity, data integrity, and quality assurance, including FDA Section 524B requirements, EU GMP Annex 11, and Computer Software Assurance (CSA) guidance. It explores the risks created when cybersecurity responsibilities fall between IT and quality teams, leaving critical systems vulnerable to security incidents and regulatory findings. It also outlines practical strategies for strengthening cybersecurity controls, establishing clear accountability, and integrating security risk management into existing quality systems. Learn how organizations can address compliance gaps, protect regulated data, and improve cybersecurity readiness across GxP environments.

2026-10-23T16:24:15+00:00October 23rd, 2026|White Papers|

The Clinical-to-Commercial Quality Gap: Closing the Maturity Debt Before Pre-Approval Inspection

Transitioning from clinical development to commercial manufacturing presents significant challenges for pharmaceutical, biologics, and cell and gene therapy manufacturers. This white paper examines the quality system gaps that can emerge as products advance toward commercialization, including process validation, change control, data integrity, and continued process verification. It also outlines a phase-based approach to assessing quality system maturity, aligning quality improvements with clinical milestones, and strengthening FDA pre-approval inspection readiness. Learn how organizations can address compliance gaps early, reduce the risk of approval delays, and build quality systems capable of supporting commercial manufacturing.

2026-10-20T16:37:47+00:00October 20th, 2026|White Papers|

Design Once, Comply Twice: Computerized Systems Strategy as CSA and Annex 11 Modernize Together

FDA Computer Software Assurance (CSA) and EU GMP Annex 11 are reshaping expectations for computerized systems in regulated life sciences. This white paper examines where the two frameworks align and diverge, including requirements for audit trails, cybersecurity, access management, and supplier oversight. It also outlines how organizations can build a harmonized, risk-based control strategy that supports both FDA and European compliance while reducing duplicated remediation and unnecessary rework.

2026-10-13T17:03:19+00:00October 13th, 2026|White Papers|

Beyond the Clause Map: What the Quality Management System Regulation Actually Changed

The FDA’s Quality Management System Regulation (QMSR) changes more than terminology. This white paper breaks down the changes that go beyond a simple clause-mapping exercise, including retained FDA provisions and expanded access to internal quality records. It also outlines practical steps organizations can take to assess gaps, strengthen compliance, and prepare for FDA inspections under the new framework.

2026-10-07T19:32:10+00:00October 7th, 2026|White Papers|
Go to Top